The Healthcare Specialist

Driven by Passion.
Powered by Science.

Passion is our driver and science is our foundation. At Rhenman & Partners we only invest in the healthcare sector and our investment process takes both scientific and financial aspects into consideration. The portfolio managers are supported in their investment decisions through close collaboration with our Scientific Advisory Board, which consists of experts within different medical fields. 

Rhenman Healthcare Equity L/S is an AIF which is available to retail investors in Sweden and Finland only, and it is registered for professional investors only in Belgium, Finland, the Netherlands, Italy, Sweden, the United Kingdom, Singapore with restricted scheme offered to accredited investors only and Switzerland (distributed without FINMA registration.)

Fonden vi förvaltar har stigit med 885%* sedan start 2009.

*As of XX-XX-XXXX (IC1 EUR)
+ 0 %

Rhenman Healthcare Equity L/S (RHE L/S)

Rhenman Healthcare Equity L/S (RHE L/S)
August 2025
The fund performance is calculated and reported once a month.
FUND CLASSNAVDEVELOPMENT 1 MONTHTHIS YEARSINCE FUND STARTSTART DATE
IC1 (EUR)800.406.29%-12.67%700.40%2009-06-22
IC3 (EUR)1037.086.35%-12.24%937.08%2009-07-31
IC2 (SEK)645.335.44%-15.19%545.33%2012-12-31
ID1 (SEK)
Distributing
352.235.40%-19.14%252.23%2012-04-30
IC1 (USD)211.588.71%-1.33%111.58%2015-01-31
RC1 (EUR)678.726.24%-12.98%578.72%2010-08-31
RC1 (SEK)737.815.35%-15.77%637.81%2009-06-22
RC2 (SEK)791.685.39%-15.49%691.68%2009-06-22

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.

 

Rhenman Healthcare Equity L/S

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.

Rhenman Healthcare Equity L/S (RHE L/S)
August 2025
The fund performance is calculated and reported once a month.
FUND CLASSNAVDEVELOPMENT 1 MONTHTHIS YEARSINCE FUND STARTSTART DATE
IC1 (EUR)800.406.29%-12.67%700.40%2009-06-22
IC3 (EUR)1037.086.35%-12.24%937.08%2009-07-31
IC2 (SEK)645.335.44%-15.19%545.33%2012-12-31
ID1 (SEK)
Distributing
352.235.40%-19.14%252.23%2012-04-30
IC1 (USD)211.588.71%-1.33%111.58%2015-01-31
RC1 (EUR)678.726.24%-12.98%578.72%2010-08-31
RC1 (SEK)737.815.35%-15.77%637.81%2009-06-22
RC2 (SEK)791.685.39%-15.49%691.68%2009-06-22

This is Rhenman & Partners

Who we are

A team of healthcare specialists.

One of the key drivers of our success is our team of engaged portfolio managers, each specializing in a specific sub-sector - pharmaceuticals, biotech, medical technology, and healthcare services.

Their in-depth expertise is complemented by ongoing access to our Scientific Advisory Board, enabling them to identify emerging trends, breakthrough innovation and high-potential companies at an early stage.

The science behind
our portfolio managers.

Our dedicated Scientific Advisory Board consists of eminent medical experts, each with their own broad network of medical researchers and specialists around the world. This collaborative process provides invaluable insights for our investment decisions and enables us to take a higher, yet more balanced level of risk.

Our unique scientific
working method.

Our way of working is built upon a well-tried, quality-assured investment strategy.

Portfolio managers with expert knowledge

Our portfolio managers have a deep level of expertise within the sub-sectors: pharmaceuticals, biotech, medical technology and healthcare services.

Backed by our Scientific Advisory Board

Förvaltarna stämmer regelbundet av sina analyser med det vetenskapliga rådet, som består av välrenommerade medicinska experter med forskarkollegor världen över.

A mandate to take on risk

Thanks to our scientific method, our in-depth analysis, and our more flexible investment mandate, we are able to take on a higher, yet more balanced level of risk.

A sector with potential

The healthcare sector is characterized by research and innovation and is driven by megatrends, such as, population growth, higher living standards and digitalization.

Responsible investments

We work actively to make long-term, sustainable and responsible investments, and our portfolio managers carefully select fund holdings based on thorough company analyses.

Together, we make the world a little healthier

By investing in healthcare, innovations within medical research receive support which in turn helps make the world a little healthier and improves people’s quality of life.

News

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Summer Series summary: Healthcare – why now?

Monthly comment (July 2025): A paradoxical situation

Monthly comment (June 25): A month of contrasts

Monthly comment (May 25): Another month overshadowed by worries over tariffs and trade barriers

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman & Partners strengthens its Operations Team

Monthly comment – January 2025: All sectors except technology closing in positive territory

Monthly comment – December 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Monthly summary – September 2024

Monthly summary – August 2024

Monthly update – July 2024

Monthly summary – June 2024

Monthly summary – May 2024

Monthly summary – April

Monthly summary – January 2024

Monthly summary – March 2023

Subscribe to ‘News’

Read interesting news, the portfolio managers’ insights and the latest developments in the fund.

EN